The gut metagenome has been implicated as an environmental factor influencing adiposity and obesity by modulating host lipid metabolism[@b1][@b2][@b3][@b4]. The gut microbiota is also a source of inflammatory molecules such as lipopolysaccharide and peptidoglycan that may contribute to metabolic disease[@b2][@b5][@b6]. Whole-genome metagenomic sequencing has provided knowledge about the structure of the human gut microbiome and identified a large number of genes and direct links to functional information[@b7][@b8]. Links between the gut metagenome and human diseases have been investigated, showing that obesity is associated with alterations in the gut metagenome and reduced bacterial diversity[@b9]. Going beyond traditional comparative analysis of functional components, the integration of metagenomic data with metabolic network analysis provides deeper understanding of metabolic capabilities of the metagenome[@b10], and this approach could be very useful for mechanistically delineating the link between the gut metagenome and human health.

Atherosclerotic disease, with manifestations such as myocardial infarction and stroke, is characterized by accumulation of cholesterol and recruitment of macrophages to the arterial wall. The gut microbiota has been shown to metabolize the dietary lipid phosphatidylcholine to trimethyl amine, which promotes atherosclerosis and inflammation in mice, furthermore levels of choline, trimethylamine N-oxide and betaine have been found to predict cardiovascular disease (CVD) risk in humans[@b11]. In a recent study, we pyrosequenced the 16*S* rRNA gene and showed that atherosclerotic plaques contain bacterial DNA with phylotypes common to the gut microbiota and that the amount of bacterial DNA in the plaque correlated with inflammation[@b12]. However, it is unclear whether atherosclerosis is associated with alterations in the composition of the gut metagenome.

To address this issue, we sequenced the gut metagenomes of patients with symptomatic atherosclerotic plaques and gender- and age-matched controls without large vulnerable plaques in the carotid arteries. To analyse the data, we developed and used a bioinformatics pipeline, Metagenomic Data Utilization and Analysis, (MEDUSA) that, besides identification of species abundance, also allows for *de novo* assembly and the identification of enriched metabolic functions in the metagenome. Our data show that patients were enriched in the genus *Collinsella* whereas controls were enriched in *Eubacterium* and *Roseburia.* At the functional level, patient metagenomes were enriched in genes encoding peptidoglycan biosynthesis whereas those of healthy controls were enriched in phytoene dehydrogenase genes.

Results
=======

Taxonomic characterization of the gut microbiota
------------------------------------------------

To address whether the gut metagenome is associated with symptomatic atherosclerosis, we sequenced the fecal metagenome of 12 patients with symptomatic atherosclerotic plaques (who had undergone carotid endarterectomy for minor ischemic stroke, transient ischemic attack or amaurosis fugax) and 13 gender- and age-matched controls without large vulnerable plaques in the carotid arteries ([Table 1](#t1){ref-type="table"}). In total, we generated 337 million 100 bp paired-end reads (12.5±4.7 (s.d.) million reads per sample) that, first, were trimmed and filtered to only contain non-human reads longer than 35 bp ([Fig. 1a](#f1){ref-type="fig"}). To determine the composition of the gut microbiota, we aligned the reads to a catalog of 2,382 non-redundant reference genomes ([Supplementary Data 1](#S1){ref-type="supplementary-material"}) collected from National Center for Biological Information (NCBI) and Human Microbiome Project catalog (<http://hmpdacc.org>). On average, 28% of the reads in a sample could be aligned to any reference genome, which is close to the 31% found in a previous metagenomic study using Illumina reads[@b7]. The majority (98±4% (s.d.) of aligned reads were bacterial and dominated by the phyla Firmicutes and Bacteroides, representing 56% and 29% of the microbiota, respectively, followed by Actinobacteria (6%) and Proteobacteria (4%; [Supplementary Fig. S1](#S1){ref-type="supplementary-material"}). This distribution is in agreement with previous observations[@b13][@b14]. The archael phylum Euryarchaeota was also present but with a high inter-subject variation (2.0±4.3% (s.d.); [Supplementary Fig. S1](#S1){ref-type="supplementary-material"}) and was dominated by the species *Methanobrevibacter smithii*, which constituted at least 93% of the reads assigned to Euryarchaeota in any individual. *Bacteroides, Ruminococcus, Eubacterium* and *Faecalibacterium* were the most abundant genera in our cohort ([Supplementary Fig. S2](#S1){ref-type="supplementary-material"}) as found previously[@b7][@b13]. Species and genome level abundances were also calculated ([Supplementary Figs S3 and S4](#S1){ref-type="supplementary-material"}), and *Faecalibacterium prausnitzii* was shown to be the most abundant species. At coverage of at least 1% of aligned reads to reference genomes, we identified 82 species in all 27 subjects making up the core microbiota in our cohort ([Supplementary Data 2](#S1){ref-type="supplementary-material"}). By contrast, the MetaHIT study identified 18 species in their total cohort of 124 individuals and 75 in half of the individuals at 1% coverage[@b7]. This difference may be explained by the fact that our cohort was smaller and more homogenous (that is, individuals of a similar age living in the same area) than the MetaHIT cohort, which included healthy subjects as well as patients with obesity or inflammatory bowel disease from different countries.

PCA and enterotypes in the cohort
---------------------------------

An instrumental principal component analysis with the health status as instrumental variable revealed that the microbial species abundance separated patients and healthy controls ([Fig. 1b](#f1){ref-type="fig"}, *P*=1e−4, Monte Carlo simulation). The genus *Collinsella* was enriched in patients whereas *Eubacterium* and *Roseburia* and three species of *Bacteroides* were enriched in control subjects ((adjusted) adj. *P*\<0.05, Wilcoxon rank-sum test; [Fig. 1c](#f1){ref-type="fig"}). Several bacterial groups correlated with cardiovascular risk factors ([Fig. 1d](#f1){ref-type="fig"}); in particular, genera of *Clostridiales, Clostridium* sp. SS2/1 and the poorly characterized butyrate-producing bacterium SSC/2 negatively correlated with the inflammatory marker high-sensitivity C-reactive protein (hsCRP; [Fig. 1d](#f1){ref-type="fig"} and [Supplementary Fig. S5](#S1){ref-type="supplementary-material"}).

A recent study suggests that the human gut microbiota can be stratified into three enterotypes of distinct microbial compositions[@b13]. We analysed our samples according to this earlier study[@b13], calculated the Jensen--Shannon distance of the genus abundance and clustered samples with partitioning around mediods. The Calinski--Harabasz index indicated that the optimal number of clusters was three ([Fig. 2a](#f2){ref-type="fig"} and [Supplementary Fig. S6](#S1){ref-type="supplementary-material"}). However, when the average silhouette index was used to assess the quality of the clusters, we saw the highest silhouette index with two clusters ([Supplementary Figs S6--7](#S1){ref-type="supplementary-material"}), which has also been observed previously[@b15]. We chose, however, to use three clusters as proposed in the publication by Arumugam *et al*.[@b13], which is the largest enterotypes study to date. The three enterotypes that we observed were characterized by the same contributors at the genus level as shown previously[@b13]: *Bacteroides* contributed to enterotype 1, *Prevotella* contributed to entrotype 2 and *Ruminococcus* contributed to enterotype 3 ([Fig. 2b](#f2){ref-type="fig"} and [Supplementary Fig. S8](#S1){ref-type="supplementary-material"}). However, as described previously[@b13], the third enterotype may be identified by different contributors depending on the source of sequence data and we found this cluster to be characterized by low levels of *Bacteroides* and *Prevotella* rather than a dominant genus ([Supplementary Fig. S8](#S1){ref-type="supplementary-material"}). To test whether the enterotypes were associated with disease status, we used Fisher's exact test and showed that patients were underrepresented in enterotype 1 (*P*=0.0048, Fisher's exact test) and overrepresented in enterotype 3 (*P*=0.047, Fisher's exact test; [Supplementary Table S1](#S1){ref-type="supplementary-material"}).

Metabolic functions of the gut microbiota
-----------------------------------------

To discover new genes in the metagenome, we performed *de novo* assembly of the sequence data, first for each individual sample separately and subsequently for a pool of all the non-assembled data from the individual samples to create one global gene catalog of our cohort. A total of 1.7 Gbp of contigs longer than 500 bp could be assembled and with a N50 value of 1.8 kbp using 3 as coverage cutoff and kmer of 31. MetaGeneMark[@b16] was used to predict genes from the contig set and 2.6 million open reading frames representing 1.4 million non-redundant genes were found. The genes were functionally annotated to KEGG, Pfam and carbohydrate active enzyme (CAZy) databases and their relative abundance was assessed. On average, 60% of the reads could be aligned to the set of contigs, which is substantially more than the percentage of reads (28%) that could be aligned to the reference genomes. This indicates that our gene catalog contains a majority of the sequenced microbiome.

A global analysis of the abundance of KEGG orthologies (KO) resulted in separation of the patient group from the control group ([Supplementary Fig. S9](#S1){ref-type="supplementary-material"}). In total, 225 KOs were differentially abundant (adj. *P*\<0.05, Wilcoxon rank-sum test), illustrating that there were functional aspects of the gut metagenome associated with symptomatic atherosclerosis. Enriched metabolic functions in the metagenomes of patients and controls can be assessed by integrating the relative gene abundance with metabolic networks. We used the reporter feature algorithm[@b17][@b18], and based on the KEGG metabolic network and the pathway associations for the KOs together with the corrected *P*-values, we identified first, reporter pathways (for example, pathways containing several significantly differentially abundant KOs; [Supplementary Table S2](#S1){ref-type="supplementary-material"}) and second reporter metabolites (for example, metabolites around which there are enzymatic reactions with associated KO differentially abundant; [Supplementary Table S3](#S1){ref-type="supplementary-material"}).

The peptidoglycan biosynthesis pathway was the highest scoring reporter pathway; eight peptidoglycan biosynthetic KOs were enriched in the gut metagenomes of patients and one was enriched in controls (adj. *P*\<0.05, Wilcoxon rank-sum test, [Fig. 3a](#f3){ref-type="fig"}). Consequently, we also found several of the metabolites in the peptidoglycan pathway to be reporter metabolites, for example, UDP-*N*-acetyl-[D]{.smallcaps}-glucosamine, which is a key precursor for peptidoglycan, indicating significant changes in KOs linked to these metabolites. There were also features of the metagenome that correlated negatively with inflammation, the highest scoring association being butyrate-acetoacetate CoA-transferase (K01036) with hsCRP (Spearman's *ρ*=−0.73, adj. *P*=0.04). These findings are in agreement with a previous study showing that butyrate is an important negative regulator of inflammation[@b19]. To investigate the origin of the butyrate-acetoacetate CoA-transferase genes, we performed a BLASTP search and identified the source as *Clostridium* sp. SS2/1; as discussed above, this species also negatively correlated with hsCRP ([Fig. 1d](#f1){ref-type="fig"} and [Supplementary Fig. S5](#S1){ref-type="supplementary-material"}).

A recent metabolomics study showed that three microbially modulated metabolites of dietary phosphatidylcholine metabolism (choline, trimethylamine N-oxide and betaine) correlate with CVD in humans[@b11]. We reconstructed the metabolic pathway from phosphatidylcholine to trimethylamine ([Supplementary Fig. S10](#S1){ref-type="supplementary-material"}) but did not observe any significant association of gene abundance in this pathway with atherosclerosis. However, we observed a positive correlation between plasma triglycerides and the abundance of several KOs in the pathway for fatty acid metabolism, specifically β-oxidation ([Fig. 3b](#f3){ref-type="fig"}, [Supplementary Fig. S11](#S1){ref-type="supplementary-material"}), which suggests a strong interaction between the gut microbiota and dietary components. We also observed that the GS-GOGAT system, which the microbiota uses for assimilation of nitrogen into amino acids, was significantly enriched in the patient group ([Fig. 3c](#f3){ref-type="fig"}). In particular, the ATP-dependent reaction carried out by glutamine synthase (adj. *P*=0.035, Wilcoxon rank-sum test) and the glutamate synthase large and small subunits (adj. *P*=0.013 and adj. *P*=0.0074, Wilcoxon rank-sum test, respectively) were enriched in patient microbiota. The ATP-independent glutamate dehydrogenase was not found to be different between the groups.

Interestingly, phytoene dehydrogenase (K10027), which is involved in the metabolism of lipid-soluble antioxidants (such as the carotenoids lycopene and β-carotene), was the KO most significantly enriched in controls in our study (adj. *P*=0.0046, Wilcoxon rank-sum test, [Fig. 4](#f4){ref-type="fig"}). To determine the phylogenetic origin of the 13 genes annotated as phytoene dehydrogenases in this study, we used BLASTP to search for related sequences in the NCBI nr database. Seven of the genes matched to *Bacteroides*, two to *Clostridia,* two to *Prevotella* and the remaining two to Actinobacteria and various Bacteroidetes. We evaluated whether the enrichment of phytoene dehydrogenase was accompanied by increased levels of carotenoids, and found increased levels of β-carotene (*P*=0.05, Student's *t*-test), but not lycopene, in serum of healthy controls compared with patients ([Fig. 4](#f4){ref-type="fig"}, [Supplementary Figs S12--13](#S1){ref-type="supplementary-material"}).

Discussion
==========

In this study, we identified several compositional and functional alterations of the gut metagenome that may be related to symptomatic atherosclerosis. The differences in the metagenome between patients and controls did not seem to be related to smoking, diabetes or body mass index ([Supplementary Figs S14--S19](#S1){ref-type="supplementary-material"}), but these factors and the potentially modifying effects of different types of medication and diet that may be different between patients and controls require further investigation. Interestingly, we observed enrichment of patients within the *Ruminococcus* enterotype.

The metagenomes of patients were enriched in genes associated with peptidoglycan biosynthesis, which suggests that increased peptidoglycan production by the gut metagenome may contribute to symptomatic atherosclerosis by priming the innate immune system and enhancing neutrophil function. Indeed, inflammation has been identified as an important contributor to the pathogenesis of atherosclerosis[@b20]. The increased abundance of genes in this pathway cannot be explained solely by a general increase in Gram-positive bacteria because both Gram-positive and Gram-negative bacteria have peptidoglycan and even more, abundant Gram-positive groups of bacteria such as *Eubacterium* and *Roseburia* were enriched in controls.

Our finding of enriched levels of phytoene dehydrogenase in the metagenomes of healthy controls and its association with elevated levels of β-carotene in the serum may indicate that the possible production of this anti-oxidant by the gut microbiota may have a positive health benefit. Lycopene and β-carotene adipose levels are associated with a reduced risk of CVD in epidemiological studies[@b21][@b22], but several large randomized, placebo-controlled studies with durations up to 12 years have failed to show that supplementation of pure β-carotene reduces CVD risk[@b23][@b24]. However, lycopene has been related to intima-media thickness of the common carotid artery[@b25] and suggested to have a role in the early stage and prevention of atherosclerosis[@b26]. A previous study encompassing \>500 participants failed to observe an association between lycopene intake and plasma lycopene levels[@b27], indicating that other mechanisms might be more important in determining plasma levels than oral intake of lycopene. Together with evidence that bacterial species from the human gut can synthesize carotenoids[@b28][@b29], we propose that our findings of increased prevalence of phytoene dehydrogenase, and increased levels of β-carotene in plasma of control subjects represent an important step towards elucidating the importance of carotenoids in the development of atherosclerosis. It is worth noting that peptidoglycan and phytoene dehydrogenase genes were not linked to obesity as there was no significant difference in abundance of these genes between lean and overweight/obese subjects in our study ([Supplementary Fig. S14](#S1){ref-type="supplementary-material"}), or in the meta-analysis of an independent study[@b13] ([Supplementary Fig. S17](#S1){ref-type="supplementary-material"}).

In conclusion, here we observed associations between enterotypes, genera and species and symptomatic atherosclerosis at the taxonomical level. Within the metagenome, genes in the peptidoglycan pathway were enriched in patients, whereas genes involved in synthesis of anti-inflammatory molecules (for example, butyrate) and antioxidants were enriched in controls, suggesting that the metagenome may contribute to the development of symptomatic atherosclerosis by acting as a regulator of host inflammatory pathways. Even though our study cannot provide evidence for direct causal effects, these findings indicate that the gut metagenome may have a role in the development of symptomatic atherosclerosis.

Methods
=======

Study design and recruitment
----------------------------

The patient samples were from the Göteborg Atheroma Study Group Biobank, which includes samples from patients who had undergone surgery to excise an atherosclerotic plaque[@b30]. The study was approved by the Ethics Committee in Gothenburg. All subjects gave written informed consent to participate after receiving oral and written information. All patients had severely stenotic plaques in the carotid artery with ipsilateral manifestations of emboli to either the brain, as minor brain infarction or transient ischemic symptoms, or to the retinal artery ([Table 1](#t1){ref-type="table"}). The clinical definition of minor brain infarction corresponds to a patient who has mild and no severe functional deficits without any need of prolonged hospital care. Hence, the underlying etiology in all these patients was a vulnerable atherosclerotic plaque with plaque rupture and embolism leading to operations with excision of the plaque[@b30]. It is not likely that the clinical events *per se* directly influenced the gut metagenome, as minor stroke has no acute effects on CRP and white blood cell count[@b31] and because the patients only had transient or minor tissue-damaging effects in the brain or eye.

The control group was selected to represent an age- and sex-matched group with no cardiovascular health problems and was recruited from two on-going population-based cohorts that have been described previously[@b32][@b33]. The investigations of the control group included repeated ultrasound examinations of the carotid and femoral arteries, and no large, potentially vulnerable plaques were detected. Further inclusion criteria in the control group were no history of CVD, no smoking, no diabetes and no treated hyperlipidemia. The underlying rationale was to avoid subjects with vulnerable plaques defined as echo-thin plaques with stenosis \>50% of vessel lumen[@b34][@b35]. Analysis of updated health records showed that one control subject had a dilation of ascending aorta as the initial recruitment as 'healthy control' and a second had white matter disease in the brain, possibly due to a small artery disease. As these diagnoses may have atherosclerosis as underlying cause, we excluded these subjects from analyses of differences between patients and controls, although they were included in specified analyses of the total cohort.

Blood samples were drawn before surgery and plasma and serum samples were prepared and immediately frozen at −70 °C. The subjects were given material and instructions for providing fecal samples at home. Methods for processing fecal samples and isolation of metagenomic DNA have been described previously[@b36].

Sequencing
----------

All samples were sequenced in the Illumina HiSeq2000 instrument at SciLifeLab in Stockholm, Sweden, with up to ten samples pooled in one lane. Libraries were prepared with a fragment length of \~300 bp. Paired-end reads were generated with 100 bp in the forward and reverse direction.

Data quality control
--------------------

Sequencing adapter sequences were removed with cutadapt (<http://code.google.com/p/cutadapt/>). The length of each read was trimmed with SolexaQA with the options '-b --p 0.05'[@b37]. Read pairs with either reads shorter than 35 bp were removed with a custom Python script. The high-quality reads were then aligned to the human genome (NCBI version 37) with Bowtie[@b38] using '-n 2 -l 35 -e 200 --best -p 8 --chunkmbs 1024 -X 600 --tryhard'. This set of high-quality reads were then used for further analysis.

Alignment to reference genomes and taxonomical analysis
-------------------------------------------------------

A set of 2,382 microbial reference genomes were obtained from the NCBI and Human Microbiome Project on 02 August 2011. The reference genomes were combined into two Bowtie indexes and the metagenomic sequence reads were aligned to the reference genomes using Bowtie with parameters '-n 2 -l 35 -e 200 --best -p 8 --chunkmbs 1024 -X 600 --tryhard'. Mapping results were merged by selecting the alignment with fewest mismatches; if a read was aligned to a reference genome with the same number of mismatches, each genome was assigned half to each genome. The relative abundance of each genome was calculated by summing the number of reads aligned to that genome divided by the genome size. In each subject, the relative abundance was scaled to sum to one. The taxonomic rank for every genome was downloaded from NCBI taxonomy to assign each genome to a species, genus and phyla. The relative abundance for each taxonomical rank was calculated buy summing the relative abundance of all its members.

*De novo* assembly and gene calling
-----------------------------------

The high-quality reads were used for *de novo* assembly with Velvet[@b39] into contigs of at least 500-bp length using 3 as coverage cutoff and kmer length of 31. To obtain long contigs with high specificity, we iteratively explored parameter values for the kmer length and coverage cutoff to balance the total assembly length and the N50 value to be used in the final *de novo* assembly. Reads from each subject were used in separate assemblies and unassembled reads were then used in a global final assembly. Genes were predicted on the contigs with MetaGeneMark[@b16]. All genes were then aligned on the contigset with Bowtie using the same parameters as above. The abundance of a gene was calculated by counting the number of reads that align to the gene normalizing by the gene length and the total number of reads aligned to any contig.

Gene annotation
---------------

The genes were annotated to the KEGG database with hidden Markov models (HMMs). Protein sequences for microbial orthologs were downloaded and aligned with MUSCLE[@b40]. HMMs were generated with HMMer3 (ref. 41) for each KO. Each gene was queried on the 4,283 HMMs and annotated the KO with lowest scoring *E*-value below 10^−20^. Out of the 2,645,414 genes, 848,353 (32%) were annotated to KOs. The genes were also annotated to CAZy[@b42]. The CAZy proteins of bacterial and archaeal origin were downloaded and HMMs were built and genes annotated as described above. The feature abundance (KOs and CAZy) was calculated by summing the abundance of genes annotated to a feature.

Genes for betaine reductase were collected from two species, *Clostridium difficile* 630 (Entrez protein accession codes Gi: 126699967 and GI: 126699969) and *Carboxydothermus hydrogenoformans* Z-2901 (Entrez protein accession codes Gi: 78044558 and GI: 78044225). The gene catalogue was searched against these four genes with USEARCH[@b43] using an *E*-value cutoff of 10^−30^.

Statistical analysis
--------------------

To determine differential abundance of metagenomic features (that is, taxonomic and functional features between patients and controls) Wilcoxon rank-sum test was applied. Strains and genera with a relative abundance in any subject above 10^−5^ and 10^−3^, respectively, were included in the analysis. Correlations were done between serum biomarkers and metagenomic features with Spearman's correlation. *P*-values were adjusted with false discovery rate with the method from Benjamini and Hochberg[@b44] when multiple hypotheses were considered simultaneously and are denoted adj. P. The R package ade4 using instrumental principal component analysis[@b45] was used to determine the global analysis of species abundance between patients and controls (in [Fig. 1b](#f1){ref-type="fig"} and [Supplementary Figs S7,S9,S18,S19](#S1){ref-type="supplementary-material"}). Monte Carlo test on the between-groups inertia percentage was performed 10,000 permutations to calculate a *P*-value in [Fig. 1b](#f1){ref-type="fig"}.

Testing the association between microbial genes and obesity
-----------------------------------------------------------

We analysed data from Arumugam *et al*.[@b13] to investigate whether the abundance of peptidoglycan and phytoene dehydrogenase genes in the gut metagenome differed between obese and lean subjects. The corresponding clusters of orthologous groups was identified to the KOs involved in peptidoglycan biosynthesis and phytoene dehydrogenase. The results are presented in [Supplementary Figs S14--S17](#S1){ref-type="supplementary-material"}. There was no significant differential abundance of the studied corresponding clusters of orthologous groups between healthy lean and obese subjects (Wilcoxon rank-sum test).

Measurement of β-carotene and lycopene
--------------------------------------

β-Carotene and lycopene were measured in the serum from healthy controls and patients using a modified protocol from[@b46]. Briefly, 200 μl of serum was mixed with 200 μl of ethanol and 8  μl of 0.191 mmol l^−1^ retinyl propionate in ethanol. Samples were vortexed gently and then 1 ml hexane was added; the samples were again vortexed (for 30 s). The phases were separated by centrifugation at 1,500*g* for 5 min and 900 μl of the upper phase was then transferred to a new tube. The samples were dried under low pressure at room temperature in a Speedvac concentrator, not to complete dryness. The residue was dissolved in 100 μl ethanol followed by addition of 100 μl acetonitrile. Samples were protected from light during handling and preparation.

The compounds were measured using a Dionex HPLC system with a C18 column, maintained at 29 °C. The mobile phase was ethanol and acetonitrile (1:1) with 0.1 ml l^−1^ diethylamine and was kept at a flow rate of 0.9 ml min^−1^. Samples were stored at 4 °C before injection of 50 μl. Chromatograms for absorbance at the wavelengths 300, 325 and 450 nm were collected simultaneously for 20 min. Peaks were identified by comparing retention time with a standard solution of β-carotene and lycopene. Quantification was based on the area under the curve.
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![Microbial composition associated with symptomatic atherosclerosis.\
(**a**) Illustration of our bioinformatics pipeline for analysing metagenome data to elucidate its relation to human metabolic disease. Sequence reads from the gut metagenome were generated with high-throughput sequencing technology and subjected to quality control. High-quality reads were used for alignment to reference genomes to estimate species abundance. *De novo* assembly of the metagenome allows for discovery of new genes not yet found in databases. Annotation of genes to KEGG allows for integration of information at the gene level with the metabolic network. Data on plasma metabolites and proteins together with gut metagenomic data constitute a basis for discovery of mechanisms for gut metagenome association with etiology of complex diseases. (**b**) Principal component analysis of microbial species abundance using health status as instrumental variable. Red is patients (P, *n*=12), green controls (C, *n*=13). The relation between microbial abundance and health status was assessed with Monte Carlo simulations with 10,000 replications by which a *P*-value was calculated. (**c**) Abundance of bacterial genera and species that differ between patients (*n*=12) with symptomatic atherosclerosis (P) and controls (*n*=13) (C). Adj. *P*\<0.05 for all. (**d**) Bacterial genera correlating with biomarkers of atherosclerosis, using Spearman's correlation. All samples, including the two excluded controls (see methods for details), were used for correlations with triglycerides, CRP (*n*=27, respectively) and white blood cell count (WBC; *n*=23). Only controls were used for low-density lipoprotein (LDL), high-density lipoprotein (HDL) and cholesterol correlations to avoid interactions with possible drug effects (*n*=15). \*Adj. *P*\<0.05, \*\*adj. *P*\<0.01 and \*\*\*adj. *P*\<0.001. Boxes denote the interquartile range (IQR) between the first and third quartiles and the line within denotes the median; whiskers denote the lowest and highest values within 1.5 times IQR from the first and third quartiles, respectively. Circles denote data points beyond the whiskers.](ncomms2266-f1){#f1}

![Symptomatic atherosclerosis correlates with gut enterotypes.\
(**a**) Three enterotypes in our cohort based on the abundance of genera. Controls and patients are denoted by filled triangles and empty triangles, respectively. Two subjects not included in the comparison are represented by empty circles. Green is enterotype 1, red is enterotype 2 and blue is enterotype 3. (**b**) Abundance of *Bacteroides*, *Prevotella* and *Ruminococcus*, proposed drivers of the three enterotypes. Boxes denote the interquartile range (IQR) between the first and third quartiles and the line within denotes the median; whiskers denote the lowest and highest values within 1.5 times IQR from the first and third quartiles, respectively. Circles denote data points beyond the whiskers.](ncomms2266-f2){#f2}

![KOs are associated with symptomatic atherosclerosis.\
(**a**) Peptidoglycan KOs were enriched in patients and eight out of nine KOs correlated positively with white blood cell levels. (**b**) β-Oxidation KOs correlate with plasma triglyceride levels. (**c**) The glutamine synthetase---glutamine oxoglutarate aminotransferase system (K00265, K00266 and K01915) with high affinity for ammonium is enriched in patients. In all panels, red indicates enriched in patients (P), green indicates enriched in controls (C). \*Adj. *P*\<0.05, \*\*adj. *P*\<0.01 and \*\*\*adj. *P*\<0.001. All samples were used for correlations with triglycerides, CRP (*n*=27, respectively) and white blood cell count (WBC; *n*=23). Only controls were used for low-density lipoprotein (LDL), high-density lipoprotein (HDL) and cholesterol correlations to avoid interactions with possible drug effects (*n*=15). Adj., adjusted.](ncomms2266-f3){#f3}

![Phytoene dehydrogenase K10027 is enriched in the gut metagenome of healthy controls.\
β-Carotene (*P*=0.05, Student's *t*-test) but not lycopene (*P*=0.35, Student's *t*-test) was enriched in serum of healthy controls. Red is patients (P), green controls (C). Boxes denote the interquartile range (IQR) between the first and third quartiles and the line within denotes the median; whiskers denote the lowest and highest values within 1.5 times IQR from the first and third quartiles, respectively. Circles denote data points beyond the whiskers.](ncomms2266-f4){#f4}

###### Characteristics of study participants.

                                              **Controls (*****n*****=13)**            **Patients (*****n*****=12)**       ***P*****-value C vs P**               **Excluded controls (*****n*****=2)**
  -------------------------------------- ---------------------------------------- ---------------------------------------- ------------------------------------- ---------------------------------------
  Males (*n*)                                               10                                       9                     1[\*](#t1-fn1){ref-type="fn"}                            2
  Age (years)                                           70.5 (0.5)                               67.6 (8.6)                0.27[†](#t1-fn2){ref-type="fn"}                        71(0)
  Current smoker (*n*)                                      0                                        4                     0.04[\*](#t1-fn1){ref-type="fn"}                         0
  Hypertension (*n*)                                        2                                        10                    0.001[\*](#t1-fn1){ref-type="fn"}                        0
  Diabetes (*n*)                                            0                                        3                     0.09[\*](#t1-fn1){ref-type="fn"}                         0
  Previous myocardial infarction (*n*)                      0                                        3                     0.09[\*](#t1-fn1){ref-type="fn"}                         0
  Statin treatment (*n*)                                    0                                        9                     \<0.001[\*](#t1-fn1){ref-type="fn"}                      0
  Aspirin                                                   0                                        12                    \<0.001[\*](#t1-fn1){ref-type="fn"}                      0
  Cerebrovascular event                                                                                                    \<0.001[\*](#t1-fn1){ref-type="fn"}                       
   Minor brain infarction (*n*)                             0                                        5                     0.01[\*](#t1-fn1){ref-type="fn"}                         0
   Transient ischemic symptoms (*n*)                        0                                        4                     0.04[\*](#t1-fn1){ref-type="fn"}                         0
   Retinal artery (*n*)                                     0                                        3                     0.09[\*](#t1-fn1){ref-type="fn"}                         0
  BMI, kg m^−2^                           23.7 (2.9)[‡](#t1-fn3){ref-type="fn"}    25.8 (2.4)[§](#t1-fn4){ref-type="fn"}   0.08[†](#t1-fn2){ref-type="fn"}                     25.6 (8.8)
  Cholesterol (mmol l^−1^)                             5.59 (1.20)                              4.62 (1.59)                0.10[†](#t1-fn2){ref-type="fn"}                     5.38 (0.62)
  Triglycerides (mmol l^−1^)                           1.19 (0.74)                              1.72 (1.08)                0.04[\|\|](#t1-fn5){ref-type="fn"}                  1.8 (0.77)
  HDL cholesterol (mmol l^−1^)                         1.67 (0.44)                              1.32 (0.26)                0.026[†](#t1-fn2){ref-type="fn"}                    1.49 (0.63)
  LDL cholesterol (mmol l^−1^)                         3.39 (1.05)                              2.53 (1.44)                0.10[†](#t1-fn2){ref-type="fn"}                     3.07 (0.91)
  ApoA1                                                1.44 (0.20)                              1.33 (0.21)                0.22[†](#t1-fn2){ref-type="fn"}                     1.46 (1.48)
  ApoB                                                 1.09 (0.29)                              0.95 (0.34)                0.27[†](#t1-fn2){ref-type="fn"}                     1.16 (0.42)
  WBC                                     5.47 (1.06)[§](#t1-fn4){ref-type="fn"}   7.78 (1.56)[‡](#t1-fn3){ref-type="fn"}  \<0.001[†](#t1-fn2){ref-type="fn"}                  5.05 (1.77)
  hsCRP (mg l^−1^)                                     2.14 (3.35)                              4.81 (5.95)                0.12[\|\|](#t1-fn5){ref-type="fn"}                  1.81 (2.27)

BMI, body mass index; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; WBC, white blood cell count.

Data are mean (s.d.) unless otherwise indicated.

^\*^Fisher's exact test.

^†^Welch's *t*-test.

^‡^*n*=11.

^§^*n*=10.

^\|\|^Wilcoxon rank-sum test.
